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Abstract
Objective: To evaluate the criteria for the prescription of oral bisphosphonates (OB) in a series of women with 
osteoporosis referred for tooth extraction. 
Study design: The study included 38 postmenopausal women on treatment with OBs. The following variables 
were analysed: age, weight, height, type of OB and duration of treatment, bone densitometry and risk factors for 
osteoporosis. In addition, the osteoporosis self-assessment tool (OST) was administered and collagen type I C-
telopeptide (CTX) levels were measured.
Results: Bone densitometry had only been performed in six patients (15.7%) before starting OB treatment. Based 
on the results of the OST, nine (23.6%) of the participants presented a low risk of osteoporosis. CTX levels were 
measured in 23 patients: 11 (47.8%) presented values below 150 pg/ml.
Conclusion: Although all patients in the present series were on treatment with OBs, a large percentage did not 
satisfy the criteria for the initiation of treatment for postmenopausal osteoporosis.
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Introduction
Osteoporosis is defined as a skeletal disorder charac-
terised by a reduction of the bone mass and a structural 
deterioration of bone tissue, leading to increased bone 
fragility. It mainly affects postmenopausal women and 
is associated with significant morbidity due to an in-
creased risk of fractures (1). A number of pharmaco-
logical and non-pharmacological therapeutic initiatives 
have been proposed to prevent and treat postmenopausal 
osteoporosis. In Spain this has led to a steady increase 
in recent years in the prescription of drugs to combat 
the disease, particularly oral bisphosphonates (OB) (2). 
The efficacy of the OBs is related to their ability to in-
hibit bone resorption, the clinical correlate of which is a 
significant reduction in the prevalence of vertebral and 
non-vertebral fractures in postmenopausal women with 
osteoporosis (3). 
New adverse effects of the prolonged administration 
of bisphosphonates have been detected in recent years; 
one of these, particularly important due to its associ-
ated morbidity, is osteonecrosis of the jaws (ONJ). 
Bisphosphonate-related ONJ is defined as an area of 
bone exposure in the maxillofacial region that persists 
for more than eight weeks in patients treated with bi-
sphosphonates (at the time of the lesion or previously) 
and who have not received radiotherapy to that anatomi-
cal region. The management of established lesions of 
ONJ is complex and may require disfiguring surgical 
treatments with major functional and cosmetic seque-
lae. Although the relationship between treatment with 
bisphosphonates and ONJ is based on solid epidemio-
logical evidence, osteonecrosis attributable to the use 
of OBs has been questioned more than that associated 
with the intravenous administration of these drugs (4). 
However, in a recently published retrospective multi-
centre study it was suggested that the relative frequency 
of ONJ in patients with osteoporosis treated with OBs 
is higher than previously estimated (5). Thus, if the pre-
scription of OBs to some patients were not correctly 
indicated, they would be unnecessarily exposed to an 
increased risk of ONJ. 
As tooth extractions are considered to be the principal 
trigger of OB-related ONJ (6), the present study was de-
signed to evaluate the criteria applied for the prescrip-
tion of OB in a series of postmenopausal women attend-
ing a dental clinic for tooth extractions. 
Material and Methods 
The study group comprised 38 postmenopausal women 
who were on treatment with OBs for osteoporosis and 
who came to a primary care buccodental health unit of 
the Galician Health Service (SERGAS) for tooth extrac-
tions during the period between June 2009 and June 
2010. The mean age of the participants was 68.7 ± 7.6 
years (range: 54-92 years). None of the women devel-
oped ONJ after performing the extraction (follow-up 
period: 3-12 months).
All the patients filled in a standardised health question-
naire to obtain the variables of interest, and the informa-
tion was completed from a review of their medical his-
tories in the computerised SERGAS data base. The fol-
lowing variables were analysed: age, weight, height, type 
of OB and duration of the treatment, bone densitometry 
study (dual x-ray absorptiometry [DXA]) and risk factors 
for osteoporosis (Table 1). In addition, the osteoporosis 
Age (years) 
68.7±7.6 (range: 54-92) 
d 65 years 
14 (36.8%) 
> 65 years 
24 (63.1%) 
History of fractures 
No
26 (68.4%) 
Yes
12 (31.5%) 
Tibia or fibula= 5/12 
Wrist= 3/12 
Patella= 2/12 
Phalanx of a toe = 2/12 
Osteoporosis self-assessment 
tool score 
t2
9 (23.6%) 
<2
29 (76.3%) 

Table 1. Risk factors for osteoporosis.
self-assessment tool (OST) was administered; this esti-
mates the risk of osteoporosis according to the weight 
and age of the patient. The cut-off point for the referral of 
patients to perform DXA is a score of 2. Prior to perform-
ing the extractions, the serum levels of collagen type I 
C-telopeptide (CTX) were determined (E 170 Elecsys, 
Roche Diagnostics, Mannheim, Germany).
This project was approved by the Ethics Committee of 
the Galician Government and all participants signed a 
specific informed consent form before their inclusion in 
the study. 
Results 
The most widely used OB in the study group was alen-
dronate (50%), followed by risedronate (23.7%), iband-
ronate (23.7%) and the combination of alendronate with 
cholecalciferol (2.6%). The mean duration of treatment 
was 42.4 ± 40.4 months (range: 2-180 months); 16 pa-
tients (42.1%) had been on treatment for more than three 
years. The risk factors for osteoporosis and bisphos-
phonate-related ONJ are listed in table 1. Bone densi-
tometry had only been performed in 6 patients (15.7%) 
before starting treatment and all of them had a T-Score 
(comparison of bone mineral density of the patient with 
that of a healthy individual of 30 years of the same sex 
and ethnic origin) less than -2.5 (2.5 standard deviations 
below the referent mean). A history of presumably os-
teoporotic fractures was detected in 12 patients (31.5%) 
(Table 1). Twenty-nine participants (76.3%) were at risk 
of osteoporosis according to the results of the OST (OST 
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score <2). CTX levels were measured in 23 patients and 
the mean value was 197.7 pg/ml; eight patients (34.8%) 
presented values below 100 pg/ml, three (13%) pre-
sented levels of 100-150 pg/ml and in the remaining 12 
(52.2%) the values were over 150 pg/ml (Table 2). 
Duration of treatment with 
oral bisphosphonates 
< 3 years 
22 (57.9%) 
t 3 years 
16 (42.1%) 
Serum LEVELS OF collagen 
type I C-telopeptide* 
High risk 
< 100 pg/ml 
8 (34.8%) 
Moderate risk 
100 pg/ml 
3 (13%) 
Low risk 
> 150 pg/ml 
12 (52.2%) 
Long-term corticosteroid 
treatment  
Yes
3 (7.9%) 
No
35 (92.1%) 

Table 2. Risk factors for bisphosphonate-related osteonecrosis of 
the jaws in the present series.
*CTX levels were measured in 23 patients.
Discussion 
In recent years there has been an alarming increase in 
the number of cases of ONJ in patients treated with OBs. 
Many of these patients present a poor oral health status 
(in the present series, 35.5% of the patients had calculus 
and the depth of periodontal probing was greater than 6 
mm in 16.1%), meaning they have considerable require-
ments for dental treatment, including tooth extractions. 
This dental procedure is considered to be the most com-
mon triggering factor for OB-related ONJ (6). The man-
agement of established ONJ lesions is complex and the 
clinical course is difficult to predict; prevention and the 
control of risk factors is thus very important. One of the 
initial strategies to prevent ONJ associated with the ad-
ministration of OBs to patients with osteoporosis would 
therefore be appropriate supervision of the prescription 
of these drugs. 
Bone mineral density (BMD) is fundamental to the de-
cision on whether or not to start pharmacological treat-
ment of osteoporosis (7). DXA of the lumbar column 
and/or of the hip is the most reliable technique to de-
termine the BMD (8) and the World Health Organisa-
tion defines osteoporosis as a BMD T-score equal to 
or less than -2.5. Numerous guidelines, protocols and 
recommendations on strategies for the prevention and 
treatment of osteoporosis have been published, but the 
indication for densitometry continues to be a subject 
of controversy. In general, pharmacological treatment 
is administered to patients with a BMD T-Score equal 
to or less than -2.5, to those with a BMD T-score less 
than -2 in association with multiple risk factors, and 
to those with a history of osteoporotic fractures of the 
vertebral column or of the hip (9). Although a decrease 
in the BMD represents one of the most important risk 
factors for fractures due to osteoporosis, DXA had only 
been performed in 15% of patients in the present study. 
Another risk indicator commonly used to justify the ini-
tiation of pharmacological treatment for osteoporosis is 
a history of vertebral or hip fractures; this risk factor 
was not detected in any of the patients evaluated in the 
present study, although 31.5% of them presented frac-
tures presumably of osteoporotic origin at other sites. 
In a recently published study performed by Felipe et al. 
(10) in a primary care centre in Parla, Madrid, Spain, it 
was found that only 51.8% of patients who were receiv-
ing treatment for osteoporosis satisfied the prescription 
criteria. On reviewing the medical histories, those au-
thors found no record of a DXA scan in the majority 
of cases (73.1%) and that 39.5% of the patients had suf-
fered at least one osteoporotic fracture. It was suggested 
that these results could be indicative of the difficulty of 
access to DXA in the Spanish national health system. 
As it is not feasible to determine the BMD in all at-risk 
patients in many countries in which access to DXA is 
not straightforward, a number of clinical-decision tools, 
principally in the form of simple questionnaires on the 
risk factors for osteoporosis, have been designed to 
identify those women with a low BMD who should be 
referred for DXA. In the present study we used the OST, 
as this is considered to be a useful index for identifying 
postmenopausal women with a low BMD (11). Based on 
the OST scores, 23.6% of the patients evaluated were 
classified as being at low risk and therefore referral for 
DXA would not be indicated. 
The measurement of CTX levels has been recommend-
ed to establish the risk of bisphosphonate-related ONJ 
and to aid decision-taking in the dental setting, particu-
larly with respect to surgical procedures (12). However, 
the usefulness of this parameter has subsequently been 
questioned and some authors do not consider it should 
be used routinely for this purpose (13,14). In a recently 
published study by Lazarovici et al. (15), it was dem-
onstrated that there was a five-fold increase in the risk 
of developing bisphosphonate-related ONJ in subjects 
with CTX levels below 150 pg/ml compared to individ-
uals with higher levels. Although 47.8% of the patients 
in the present study were identified as being at high risk 
according to the criteria proposed by Marx et al. (12), 
none developed ONJ after tooth extraction. 
Osteoporosis is a major public health problem because it 
significantly increases the risk of fractures, particularly 
in untreated patients. In general, it is accepted that the 
benefits derived from treatment with OBs are greater 
than the relatively small risk of developing ONJ. Al-
though all the patients in the present series were receiv-
ing OBs, the majority did not satisfy the criteria for the 
initiation of treatment for postmenopausal osteoporo-
sis. Different protocols for the treatment of osteoporo-
sis in postmenopausal women have been proposed aid 
decision-taking in the two most controversial aspects of 
osteoporosis: in which patients to perform DXA and in 
which to start pharmacological treatment (1,9). Adher-
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ence to standardised guidelines for the prescription of 
OBs in postmenopausal women could therefore help to 
improve the management of osteoporosis and reduce the 
prevalence of ONJ secondary to dental procedures. 
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